THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ --Amgen(NASDAQ: AMGN) today announced the appointment ofDavid W. Gibbsto its Board of Directors, effective immediately. Gibbs will serve on the Board's Audit Committee andCompensation and Management Development Committee.
Gibbs recently retired as president and chief executive officer of Yum! Brands, a worldwide leader in iconic restaurant brands, includingTaco BellandKentucky Fried Chicken, following a distinguished career where he held several senior leadership positions. As CEO from 2020 to 2025, he led the company's digital transformation and expanded its global footprint to nearly 61,000 locations.
Gibbs also brings significant board experience with leading global consumer brands. He has served on the Board of Directors of Under Armour, Inc. since 2021, where he chairs the Human Capital andCompensation Committee, and PepsiCo, Inc. since 2026, where he serves on the Audit Committee.
"We are excited to welcome David toAmgen's Board. David has a proven track record leading some of the world's most recognized consumer brands, and we look forward to benefiting from his expertise," saidRobert A. Bradway, chairman and chief executive officer atAmgen. "His experience creating direct relationships with customers will help inform how we prepare for future launches and bring innovative treatments to more patients around the world."
Gibbs holds a bachelor's degree in mathematical science fromJohns Hopkins Universityand a Master of Business Administration degree fromDuke University'sFuqua School of Business.
With Gibbs' appointment, the Board will have 13 directors, 12 of whom are independent.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.